Publication

B-PRECISE-01 Study: a phase lb trial of MEN1611, a PI3K Inhibitor, combined with trastuzumab +/- fulvestrant for the treatment of HER2-positive advanced or metastatic breast cancer

Piccart-Gebhart, MJ
; 
Aftimos, PG
; 
Duhoux, FP
; 
Wildiers, H
; 
Isambert, N
; 
Campone, M
; 
Tosi, D
; 
Varga, AI
; 
Boni, V
; 
Doger, B
... show 10 more
Citations
Altmetric:
Abstract
Authors
Piccart-Gebhart, MJ
Aftimos, PG
Duhoux, FP
Wildiers, H
Isambert, N
Campone, M
Tosi, D
Varga, AI
Boni, V
Doger, B
Corbacho, JG
Jimenez-Rodriguez, B
Borrego, MR
Saura, C
Arkenau, HT
Wardley, Andrew M
Troconiz, IF
Binaschi, M
Simonelli, C
Pellacani, AU
Affiliation
Institut Jules Bordet, Universit� Libre de Bruxelles, Brussels, Belgium
Description
Date
2019
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Piccart-Gebhart MJ, Aftimos PG, Duhoux FP, Wildiers H, Isambert N, Campone M, et al. B-PRECISE-01 Study: a phase Ib trial of MEN1611, a PI3K Inhibitor, combined with trastuzumab � fulvestrant for the treatment of HER2-positive advanced or metastatic breast cancer. J Clin Oncol. 2019;37(15_suppl):TPS1101-TPS.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/622462
Embedded videos